Tummon 1988.

Study characteristics
Methods	Trial design: Randomised controlled trial
Participants	Participants:  38 women were randomised and analysed. Mean age: 31.4 ± 0.6 years Inclusion criteria: Laparoscopically diagnosed and staged endometriosis Exclusion criteria: not stated Setting: United States of America Timing: not stated
Interventions	GnRHa group: 8 women received leuprolide 1.6 mg daily intranasally, 8 women received buserelin 1.2 mg daily IN and 9 received buserelin 200 μg daily subcutaneously (n = 25) versus Danazol, 200 mg four times daily orally (n = 13)
Outcomes	Bone Mineral Density Serum E2, FSH, LH, and progesterone concentrations
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated Funding: Supported by TAP Pharmaceuticals, Abbott Laboratories, North Chicago, Illinois, and by Hoechst‐Roussel Pharmaceuticals, Somerville, New Jersey Author could not be contacted due to lack of information.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Randomly assigned". No further details of method used to generate the randomisation sequence were provided.
Allocation concealment (selection bias)	Unclear risk	No further details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details provided of blinding of participants or personnel
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided of blinding of outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information about incomplete outcome data
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected